According to a recent announcement of listed Chengdu enterprise Berry Genomics, the third-generation gene sequencer, Sequel II CNDx, developed by its subsidiary has officially received the medical device registration certificate from the National Medical Products Administration. It is worth noting that it is the world’s first third-generation gene sequencing platform approved for clinical application. This milestone marks China’s official entry into a new era of long-read and high-precision clinical gene sequencing.

 

Edited by Zhang Yuanlin

Source: Chengdu Discovery